Original from: Medcapta official

Shenzhen, China, January 24, 2022: Medcaptain Medical Technology and Penlon, a world-renowned medical device manufacturer, formally entered into an acquisition. As the first step in Medcaptain’s international M&A strategy, this acquisition is set to further strengthen Medcaptain’s position as a perioperative solution provider worldwide.

In accordance with the agreement reached between the two parties, the acquisition will consolidate Penlon’s entire business line with Medcaptain’s current business. Through this, Medcaptain has officially taken an important step in laying out its business portfolio in Medication Delivery, In-Vitro Diagnostics, Anesthesia, Respiratory, and Medical Disposables.

Penlon: a globally recognized brand with 80 years of dedicated experience

Penlon, a long-established medical device company, was founded in Oxford, England in 1943. Its business encompasses primarily manufacturing and sales of products and systems in the fields of anesthesia, intubation and suction & oxygen therapy, with products being exported to more than 90 countries across Europe, North America, the Middle East and Asia.

Penlon meets Medcaptain: a strategic partnership radiates new energy

With powerful R&D and high management capacities, Medcaptain has experienced rapid growth in recent years and expanded its business portfolio. With a global vision, the company has always been determined to become a captain in the medical device industry.

This acquisition aims to leverage Penlon's well-established product portfolio in the fields of anesthesia and respiratory care to complement Medcaptain’s existing products and give a strong boost to the current business. In the past few years, Medcaptain's high-end intelligent infusion workstation has been widely recognized in the clinical field. A series of products relying on hardcore technologies in the medication delivery field - HP-80 MRI Infusion Workstation, MS-100 Infusion Workstation and HP TCI Series Syringe Pump – have paved the way to a new era of infusion.

In the field of in-vitro diagnostics, Medcaptain continues to evolve and lead the industry with pioneering technologies, and gradually provides complete solutions in the sub-fields such as blood transfusion and coagulation, chemiluminescence and molecular diagnostics. In addition, in the field of deep vein thrombosis prevention, Medcaptain also provides a comprehensive product portfolio and high-quality services.

The strong alliance with Penlon is of great strategic importance for improving Medcaptain’s perioperative solutions and providing better support and services to clinical staff and patients. Through this acquisition, Medcaptain will also further expand its global presence and continue to increase its competitiveness in the critical care field.

Moreover, after the acquisition is completed, Penlon will join hands with Medcaptain’s R&D management team. “With Medcaptain’s strong innovation ability, highly enterprising spirit and dedication to exploration, I believe that the century-old brand will be rejuvenated, and more innovative products will be introduced in China and abroad to further consolidate its leading global position in the fields of anesthesia and respiratory care,” said Guruswamy Krishnamoorthy, CEO of Penlon.

With an open mind and a far-reaching vision, Medcaptain has always placed a strong focus on the global market. In the future, Medcaptain will work together with Penlon to accelerate innovation and ensure steady development through comprehensive and in-depth cooperation, expanding its ability to provide high-value services to the medical community worldwide and providing valuable contributions to the development of the medical device industry!

Source: Medcaptain completes acquisition of Penlon, strengthening its position as a perioperative solutions provider